The Eye Institute of Utah performs all phases of Pharmaceutical and Medical Device clinical trials. We are unique in that we have surgical capabilities on site. We have state-of-the-art facilities that offer laser vision correction, retina-vitreous, glaucoma, and cataract surgery. In both our clinical and ambulatory surgical centers, we treat all aspects of eye disease and anomalies, such as dry eye, ocular infections, and more. Clinical studies at The Eye Institute of Utah are conducted to determine the safety and effectiveness of new devices, drugs, or procedures for the treatment of various ocular diseases.
The development of medical knowledge and technology requires and depends on research sites playing an active role in the investigation and testing of products coming to market. We are experienced in pharmaceutical and pilot medical device clinical trials.
We currently have six principal investigators on-site with research experience varying from 5-40+ years. Our principal investigators are knowledgeable, experienced, and trained on GCP’s as well as the FDA Code of Regulations. Since The Eye Institute of Utah was established in 1980 as the first and largest office-based eye surgical center in Utah, we are able to enroll the vast majority of our patients from our own patient population.
Our study department has developed full-time employees dedicated to clinical research trials. Our mission is to provide outstanding support to our community, sponsors, and patients with the highest regard for patient safety and privacy. We are dedicated to excellence in the clinical research arena; we will provide the highest quality work with integrity and efficiency. We see the value of investing in clinical research so we can improve the quality of eye care for generations to come.
To learn more about our current clinical studies and find out if you are a candidate, please fill out the form below or contact our Study Department at (801) 266-2283.
The Eye Institute of Utah Doctors have either authored or reviewed and approved this content.